EcoDrugPlus

Dna Topoisomerase Ia

Ensembl ID : ENSTNIG00000007313
Gene Symbol: TOP1A
2 Cross references
207 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSTNIG00000013391
Gene Symbol: EML4
3 Cross references
207 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSTNIG00000016418
Gene Symbol: EPHA3
2 Cross references
210 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion A

Ensembl ID : ENSTNIG00000010981
Gene Symbol: FAUA
2 Cross references
300 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase A

Ensembl ID : ENSTNIG00000017221
Gene Symbol: FYNA
2 Cross references
190 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase A

Ensembl ID : ENSTNIG00000017219
Gene Symbol: FYNA
2 Cross references
190 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSTNIG00000005722
Gene Symbol: FYNB
3 Cross references
199 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSTNIG00000001505
Gene Symbol: GPR119
3 Cross references
174 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSTNIG00000002534
Gene Symbol: HCK
2 Cross references
205 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSTNIG00000003228
Gene Symbol: ITK
2 Cross references
205 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1b

Ensembl ID : ENSTNIG00000011016
Gene Symbol: IMPDH1B
3 Cross references
257 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSTNIG00000012031
Gene Symbol: IMPDH2
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).